中国药房2017，Vol.28Issue(26)：3643-3646,4.DOI:10.6039/j.issn.1001-0408.2017.26.12
北京地区2003-2013年舒血宁注射液致不良反应回顾性分析
Retrospective Analysis of ADR Induced by Shuxuening Injection in Beijing Area during 2003-2013
摘要
Abstract
OBJECTIVE:To investigate the occurrence of ADR induced by Shuxuening injection in Beijing area,and to pro-vide reference for rational drug use in clinic. METHODS:ADR induced by Shuxuening injection in Beijing area during 2003-2013 was classified statistically in respects of population,organs/systems involved in ADR,clinical manifestations,occurrence time, drug combination and prognosis. RESULTS:Of 1648 ADR cases,the incidence of ADR in the elderly patients was higher than young patients,and that of female patients (60.92％) was higher than that of male patients (39.14％). Multiple organs/systems were involved in Shuxuening injection-induced ADR,and top 3 were nervous system (422 cases,21.33％),skin and its appen-dants (411 cases,20.78％) and others (305 cases,15.42％). Clinical manifestations were skin rash,itching,dizziness and ner-vousness,palpitation,arrhythmia,etc. ADR mostly occurred within 5-30 min after medication. In ADR reports,there were a vari-ety of drugs combined with Shuxuening injection. Shuxuening injection combined with Alprostadil injection was most common(61 cases,accounting for 23.46％ of drug combination). Among 1648 ADR cases,there were 622 cured cases and 1039 cases im-proved,4 cases were not improved,3 cases had sequelae and 1 case died. CONCLUSIONS:Clinical application of Shuxuening in-jection should strictly follow the indications of drug package inserts;differentiation of symptoms and signs is based on specific dos-age,solvent,route of administration,etc. It is necessary to strengthen the prescription check,and strengthen the observation after medication especially for the elderly and other special groups so as to reduce and avoid ADR.关键词
舒血宁注射液/不良反应/分析/合理用药Key words
Shuxuening injection/ADR/Analysis/Rational drug use分类
医药卫生引用本文复制引用
朱盛,邢百倩,梅丹,冯雷,张晓..北京地区2003-2013年舒血宁注射液致不良反应回顾性分析[J].中国药房,2017,28(26):3643-3646,4.基金项目
国家临床重点专科建设项目 （）
